Skip to main content
Top
Published in: International Urology and Nephrology 3/2019

01-03-2019 | Diabetic Nephropathy | Nephrology - Original Paper

Aspirin attenuates podocyte injury in diabetic rats through overriding cyclooxygenase-2-mediated dysregulation of LDL receptor pathway

Authors: Kun Ling Ma, Liang Liu, Yang Zhang, Gui Hua Wang, Ze Bo Hu, Pei Pei Chen, Jian Lu, Chen Chen Lu, Tie Kai Gong, Yu Xiang Gong, Bi Cheng Liu

Published in: International Urology and Nephrology | Issue 3/2019

Login to get access

Abstract

Aim

This study aimed to investigate the effects of aspirin on podocyte injury and its underlying mechanisms in diabetic nephropathy (DN).

Methods

Eight-week-old male Sprague–Dawley rats were divided into three groups: non-diabetic rats (Control), streptozotocin-induced diabetic rats (DM), and diabetic rats treated with aspirin (DM + Aspirin) for 12 weeks. Intracellular lipid accumulation was evaluated by Oil Red O staining and quantitative free cholesterol assays. Podocyte injury and the levels of COX-2, inflammatory cytokines, and low-density lipoprotein receptor (LDLr) pathway-related proteins were evaluated by electron microscopy, immunohistochemical staining, and Western blotting, respectively.

Results

Lipid levels and urinary albumin–creatinine ratios were higher in the DM rats than in the Control rats. Periodic acid-Schiff staining showed glomerular hypertrophy and mild mesangial area widening in the DM rats. Electron microscopy showed that the podocyte foot processes were significantly flattened or absent in the DM rats. The protein expression levels of WT-1 and nephrin in the podocytes of DM rats were reduced. Interestingly, lipid accumulation in the kidneys of DM rats was significantly increased due to increased protein expression levels of LDLr, sterol regulatory element-binding protein (SREBP) cleavage-activating protein (SCAP), SREBP-2, cyclooxygenase-2 (COX-2), and inflammatory cytokines. Confocal immunofluorescent staining showed that COX-2 and WT-1 were co-expressed. Furthermore, COX-2 protein expression levels were positively correlated with LDLr protein expression levels. However, when COX-2 expression was inhibited by aspirin, these changes in the DM rats were significantly attenuated.

Conclusion

Aspirin attenuates podocyte injury in DN, which may be through COX-2-mediated dysregulation of LDLr pathway.
Literature
1.
go back to reference Chen J, Cui W, Zhang Q, Jia Y, Sun Y, Weng L et al (2015) Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes. Am J Transl Res 7(9):1553–1563PubMedPubMedCentral Chen J, Cui W, Zhang Q, Jia Y, Sun Y, Weng L et al (2015) Low molecular weight fucoidan ameliorates diabetic nephropathy via inhibiting epithelial-mesenchymal transition and fibrotic processes. Am J Transl Res 7(9):1553–1563PubMedPubMedCentral
2.
go back to reference Chen HC, Guh JY, Chang JM, Hsieh MC, Shin SJ, Lai YH (2005) Role of lipid control in diabetic nephropathy. Kidney Int 67(Suppl 94):S60–S62 Chen HC, Guh JY, Chang JM, Hsieh MC, Shin SJ, Lai YH (2005) Role of lipid control in diabetic nephropathy. Kidney Int 67(Suppl 94):S60–S62
3.
go back to reference Zhang Y, Ma KL, Ruan XZ, Liu BC (2016) Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury. Int J Biol Sci 12(5):569–579CrossRefPubMedPubMedCentral Zhang Y, Ma KL, Ruan XZ, Liu BC (2016) Dysregulation of the low-density lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury. Int J Biol Sci 12(5):569–579CrossRefPubMedPubMedCentral
4.
go back to reference Hao CM, Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71(11):1105–1115CrossRefPubMed Hao CM, Breyer MD (2007) Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int 71(11):1105–1115CrossRefPubMed
5.
go back to reference Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL et al (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107(7):889–898CrossRefPubMedPubMedCentral Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL et al (2001) Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 107(7):889–898CrossRefPubMedPubMedCentral
7.
go back to reference Park YG, Kang SK, Noh SH, Park KK, Chang YC, Lee YC et al (2004) PGE2 induces IL-1beta gene expression in mouse osteoblasts through a cAMP-PKA signaling pathway. Int Immunopharmacol 4(6):779–789CrossRefPubMed Park YG, Kang SK, Noh SH, Park KK, Chang YC, Lee YC et al (2004) PGE2 induces IL-1beta gene expression in mouse osteoblasts through a cAMP-PKA signaling pathway. Int Immunopharmacol 4(6):779–789CrossRefPubMed
8.
go back to reference Sugimoto Y, Inazumi T, Tsuchiya S (2015) Roles of prostaglandin receptors in female reproduction. J Biochem 157(2):73–80CrossRefPubMed Sugimoto Y, Inazumi T, Tsuchiya S (2015) Roles of prostaglandin receptors in female reproduction. J Biochem 157(2):73–80CrossRefPubMed
9.
go back to reference Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X et al (2007) Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 18(2):551–559CrossRefPubMed Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X et al (2007) Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol 18(2):551–559CrossRefPubMed
10.
go back to reference Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC (2009) Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol 20(9):1953–1962CrossRefPubMedPubMedCentral Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC (2009) Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol 20(9):1953–1962CrossRefPubMedPubMedCentral
11.
go back to reference Cheng H, Fan X, Moeckel GW, Harris RC (2011) Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J Am Soc Nephrol 22(7):1240–1251CrossRefPubMedPubMedCentral Cheng H, Fan X, Moeckel GW, Harris RC (2011) Podocyte COX-2 exacerbates diabetic nephropathy by increasing podocyte (pro)renin receptor expression. J Am Soc Nephrol 22(7):1240–1251CrossRefPubMedPubMedCentral
12.
go back to reference Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC (2002) Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62(3):929–939CrossRefPubMed Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, McKanna JA, Harris RC (2002) Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 62(3):929–939CrossRefPubMed
13.
go back to reference Quilley J, Santos M, Pedraza P (2011) Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol 300(6):H2316–H2322CrossRefPubMedPubMedCentral Quilley J, Santos M, Pedraza P (2011) Renal protective effect of chronic inhibition of COX-2 with SC-58236 in streptozotocin-diabetic rats. Am J Physiol Heart Circ Physiol 300(6):H2316–H2322CrossRefPubMedPubMedCentral
14.
go back to reference Wang JL, Cheng HF, Shappell S, Harris RC (2000) A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57(6):2334–2342CrossRefPubMed Wang JL, Cheng HF, Shappell S, Harris RC (2000) A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 57(6):2334–2342CrossRefPubMed
15.
go back to reference Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L et al (2015) Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab 308(12):E1140–E1148CrossRefPubMed Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L et al (2015) Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Am J Physiol Endocrinol Metab 308(12):E1140–E1148CrossRefPubMed
18.
go back to reference Kanasaki K, Taduri G, Koya D (2013) Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol (Lausanne) 4:7CrossRef Kanasaki K, Taduri G, Koya D (2013) Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis. Front Endocrinol (Lausanne) 4:7CrossRef
19.
go back to reference Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124(3):139–152CrossRef Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124(3):139–152CrossRef
22.
go back to reference Hirano T (2014) Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol 18(2):206–209CrossRefPubMed Hirano T (2014) Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol 18(2):206–209CrossRefPubMed
23.
go back to reference Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA et al (2000) Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11(4):669–683PubMed Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA et al (2000) Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 11(4):669–683PubMed
24.
go back to reference Ruan XZ, Varghese Z, Moorhead JF (2003) Inflammation modifies lipid-mediated renal injury. Nephrol Dial Transpl 18(1):27–32CrossRef Ruan XZ, Varghese Z, Moorhead JF (2003) Inflammation modifies lipid-mediated renal injury. Nephrol Dial Transpl 18(1):27–32CrossRef
25.
go back to reference Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L et al (2015) Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol 52(6):1045–1056CrossRefPubMed Zhang Y, Ma KL, Liu J, Wu Y, Hu ZB, Liu L et al (2015) Inflammatory stress exacerbates lipid accumulation and podocyte injuries in diabetic nephropathy. Acta Diabetol 52(6):1045–1056CrossRefPubMed
26.
go back to reference Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35(6):284–292CrossRefPubMed Alhouayek M, Muccioli GG (2014) COX-2-derived endocannabinoid metabolites as novel inflammatory mediators. Trends Pharmacol Sci 35(6):284–292CrossRefPubMed
27.
go back to reference Rajakariar R, Yaqoob MM, Gilroy DW (2006) COX-2 in inflammation and resolution. Mol Interv 6(4):199–207CrossRefPubMed Rajakariar R, Yaqoob MM, Gilroy DW (2006) COX-2 in inflammation and resolution. Mol Interv 6(4):199–207CrossRefPubMed
28.
go back to reference Goldstein SL, Leung JC, Silverstein DM (2006) Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 1(5):979–986CrossRefPubMed Goldstein SL, Leung JC, Silverstein DM (2006) Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin. Clin J Am Soc Nephrol 1(5):979–986CrossRefPubMed
29.
go back to reference Donadio JV Jr, Ilstrup DM, Holley KE, Romero JC (1988) Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study. Mayo Clin Proc 63(1):3–15CrossRefPubMed Donadio JV Jr, Ilstrup DM, Holley KE, Romero JC (1988) Platelet-inhibitor treatment of diabetic nephropathy: a 10-year prospective study. Mayo Clin Proc 63(1):3–15CrossRefPubMed
30.
go back to reference Khajehdehi P, Roozbeh J, Mostafavi H (2002) A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol 36:145–148CrossRefPubMed Khajehdehi P, Roozbeh J, Mostafavi H (2002) A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol 36:145–148CrossRefPubMed
Metadata
Title
Aspirin attenuates podocyte injury in diabetic rats through overriding cyclooxygenase-2-mediated dysregulation of LDL receptor pathway
Authors
Kun Ling Ma
Liang Liu
Yang Zhang
Gui Hua Wang
Ze Bo Hu
Pei Pei Chen
Jian Lu
Chen Chen Lu
Tie Kai Gong
Yu Xiang Gong
Bi Cheng Liu
Publication date
01-03-2019
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2019
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-2059-7

Other articles of this Issue 3/2019

International Urology and Nephrology 3/2019 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.